v3.22.2.2
Acquisition, Discontinued Operations, Equity-Method Investment and Collaborative Arrangement - Acquisitions Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Jun. 09, 2022
Mar. 11, 2022
Oct. 02, 2022
Apr. 03, 2022
Oct. 03, 2021
Oct. 02, 2022
Oct. 03, 2021
Dec. 31, 2021
Business Acquisition [Line Items]                
Acquired in-process research and development expenses [1]     $ 524   $ 762 $ 880 $ 1,000  
Payments to acquire businesses, net of cash acquired           6,225 $ 0  
Goodwill [2]     49,441     49,441   $ 49,208
Arena [Member]                
Business Acquisition [Line Items]                
Business acquisition, per share in cash (in dollars per share)   $ 100            
Payments to acquire businesses, gross   $ 6,600            
Payments to acquire businesses, net of cash acquired   6,200            
Intangible assets acquired   5,500            
Goodwill   1,000            
Net deferred tax liabilities   505            
Arena [Member] | Restructuring Charges And Acquisition-Related Costs [Member]                
Business Acquisition [Line Items]                
Post closing compensation expense   138   $ 138        
Arena [Member] | IPR&D [Member]                
Business Acquisition [Line Items]                
Intangible assets acquired   5,000            
Arena [Member] | Licensing Agreements and Other [Member]                
Business Acquisition [Line Items]                
Intangible assets acquired   $ 460            
ReViral [Member]                
Business Acquisition [Line Items]                
Asset acquisition, consideration transferred (up to) $ 536              
Payments to acquire asset 436              
Payment for asset acquisition, base payment 425              
Asset acquisition, contingent consideration 100              
Acquired in-process research and development expenses $ 426   $ 426     $ 426    
[1] See Note 1D.
[2] All goodwill is assigned within the Biopharma reportable segment. As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the third quarter of 2022 (see Note 1A), our goodwill is required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. Therefore, we have not yet completed the allocation, but it will be completed in the current year.